101574-65-6
101574-65-6 结构式
基本信息
4-羟基苯甲酸 2-[[4-(1-甲基乙基)苯基]亚甲基]肼
4-hydroxy-N'-(4-isopropylbenzylidene)benzohydrazide
(E)-4-hydroxy-N'-(4-isopropylbenzylidene)benzohydrazide
4-HYDROXY-2-[(1E)-[4-(1-METHYLETHYL)PHENYL]METHYLENE]HYDRAZIDE
2-[[4-(1-Methylethyl)phenyl]methylene]hydrazide 4-hydroxybenzoic acid
4-Hydroxybenzoic acid 2-[[4-(1-methylethyl)phenyl]methylene]hydrazide
Benzoic acid, 4-hydroxy-, 2-[[4-(1-methylethyl)phenyl]methylene]hydrazide
安全数据
常见问题列表
ERRβ/γ
Treatment of differentiated C2C12 cells with the ERRβ/γ agonist (relative to vehicle) over a 2 to 4 h time period reveals a reproducible and robust increase in the immunoreactivity of the GRα-D isoform. It is observed that MAO-A mRNA expression is significantly increased by treatment with the ERRβ/γ agonist, GSK4716. Furthermore, it is observed that GSK4716 induces the expression of the mRNAs encoding peroxisome proliferator-activated receptor-γcoactivator 1α (PGC-1α) and PGC-1β (key regulator of many metabolic genes) identified as direct coactivators for the ERR family. GSK4716 induces the expression of PGC-1 and genes involved in fatty acid oxidation in concordance with the characterized role of ERRγ in cardiac metabolism. Treatment of primary mouse myotubes with GSK4716, an ERRβ/γ agonist, results in a concerted increase in the expression levels of Ppargc1a , Ppargc1b , and the Esrr genes. Furthermore, Cpt1b , Atp5b , and Idh3 , genes in key mitochondrial pathways, are also induced by GSK4716. Additionally, GSK4716 increases citrate synthase activity and cytochrome c protein levels.